User:Mr. Ibrahem/Rezafungin
 | |
| Clinical data | |
|---|---|
| Trade names | Rezzayo |
| Other names | Biafungin; CD101 |
| License data |
|
| Drug class | Echinocandin[1] |
| Chemical and physical data | |
| Formula | C63H85N8O17+ |
| Molar mass | 1226.4 g/mol |
Rezafungin, sold under the brand name Rezzayo, is an antifungal medication used to treat invasive candidiasis, including candidemia.[1] Specifically it is used in adults with few or no alternative treatment options.[1][2] It is given by slow injection into a vein.[1]
Common side effects include low potassium, fever, diarrhea, nausea, low magnesium, abdominal pain, and constipation.[1] Other side effects may include infusion reactions, sun sensitivity, and liver problems.[1] Safety in pregnancy is unclear.[1] It is in the echinocandin class of medication.[1][3]
Rezafungin was approved for medical use in the United States in 2023.[1] It is expected to become available in the United States in the summer of 2023 and to be expensive.[4] It received an orphan medication designation in Europe in 2021.[5]
References[edit]
- ^ a b c d e f g h i j k "DailyMed - REZZAYO- rezafungin injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 2 July 2023. Retrieved 21 June 2023.
- ^ "Rezzayo approved by FDA amid rapid Candida auris spread". thepharmaletter.com. March 23, 2023. Archived from the original on July 1, 2023. Retrieved April 4, 2023.
- ^ Zhao Y, Perlin DS (September 2020). "Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data". Journal of Fungi. 6 (4): 192. doi:10.3390/jof6040192. PMC 7712954. PMID 32998224.
- ^ "Rezafungin (Rezzayo)". IDStewardship. 23 March 2023. Archived from the original on 12 May 2023. Retrieved 21 June 2023.
- ^ "EU/3/20/2385". European Medicines Agency. 18 May 2021. Archived from the original on 1 April 2023. Retrieved 22 June 2023.